Humacyte regains ex-U.S. rights to Symvess from Fresenius, pays low-single-digit royalties

Humacyte, Inc.

Humacyte obtains sole worldwide rights to develop and commercialize Symvess; Fresenius retains U.S. distribution terms unchanged.
Humacyte will pay low-single-digit royalties on ex-U.S. net sales, with a two-year royalty-free period after launch in each country.
Existing U.S. royalties to Fresenius remain at mid-single to low double digits; Fresenius must adopt Symvess as standard of care in hemodialysis if supported.
Positions Humacyte to advance discussions with corporate partners for international and indication-specific rights.
Humacyte CEO highlights planned international expansion in Saudi Arabia and Israel for vascular injury repair.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Humacyte, Inc. amended Third Amendment to Distribution Agreement with Fresenius Medical Care Holdings, Inc. valued at low-single-digit royalties on net sales (effective 2026-04-21).

Action: amendment
Agreement: supply
Counterparty: Fresenius Medical Care Holdings, Inc.
Value: low-single-digit royalties on net sales
Effective: 2026-04-21

Exact text from the filing

On April 21, 2026, Humacyte, Inc. (the “Company”) entered into the Third Amendment to Distribution Agreement (the “Amendment”) with Fresenius Medical Care Holdings, Inc. (“Fresenius”), to amend the Distribution Agreement, dated as of June 25, 2018, as amended, between the Company and Fresenius (the “Agreement”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-048164

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.